Metastatic Ovarian Cancer Pipeline Insights Report 2016 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets (
has announced the addition of the “Metastatic
Ovarian Cancer-Pipeline Insights, 2016”
report to their

Metastatic Ovarian Cancer-Pipeline Insights, 2016 provides in depth
insights on the pipeline drugs and their development activities around
the Metastatic Ovarian Cancer. The report covers the product profiles in
various stages of development including Discovery, Pre-clinical, IND,
Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other
development activities including technology, licensing, collaborations,
acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and
dormant drugs that have gone inactive over the years for Metastatic
Ovarian Cancer.

The report also assesses the Metastatic Ovarian Cancer therapeutics by
Monotherapy, Combination products, molecule type and Route of


  • The report provides competitive pipeline landscape of Metastatic
    Ovarian Cancer
  • The report provides pipeline products under drug profile section which
    includes product description, MOA, licensors & collaborators,
    development partner and chemical information
  • Coverage of the Metastatic Ovarian Cancer pipeline on the basis of
    target, MOA, route of administration, technology involved and molecule
  • The report reviews key players involved in the therapeutics
    development for Metastatic Ovarian Cancer and also provide company
  • The report also gives the information of dormant and discontinued
    pipeline projects
  • Pipeline products coverage based on various stages of development
    ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development and molecule type

Key Topics Covered:

  1. Metastatic Ovarian Cancer Overview
  2. Metastatic Ovarian Cancer Pipeline Therapeutics
  3. Metastatic Ovarian Cancer Therapeutics under Development by Companies
  4. Metastatic Ovarian Cancer Filed and Phase III Products
  5. Comparative Analysis
  6. Metastatic Ovarian Cancer Phase II Products
  7. Metastatic Ovarian Cancer Phase I and IND Filed Products
  8. Metastatic Ovarian Cancer Discovery and Pre-Clinical Stage Products
  9. Metastatic Ovarian Cancer – Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Metastatic Ovarian Cancer – Discontinued Products
  15. Metastatic Ovarian Cancer – Dormant Products
  16. Companies Involved in Therapeutics Development for Metastatic Ovarian

For more information visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women’s
, Ovarian